NZ629888B2 - Antibodies to matrix metalloproteinase 9 - Google Patents

Abstract

Disclosed is a method of detecting human MMP9 in a sample, comprising: a) contacting the sample with an antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region and a light chain variable (VL), wherein the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 34, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 35, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 36; wherein the light chain variable domain (VL) comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39; and b) detecting binding of the antibody or antigen-binding fragment thereof to human MMP9 in the sample, thereby detecting the presence or absence of the human MMP9. e amino acid sequence set forth in SEQ ID NO: 34, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 35, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 36; wherein the light chain variable domain (VL) comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39; and b) detecting binding of the antibody or antigen-binding fragment thereof to human MMP9 in the sample, thereby detecting the presence or absence of the human MMP9.

Description

ANTIBODIES TO MATRIX METALLOPROTEINASE 9 REFERENCE TO SE UENCE LISTING SUBMITTED VIA B The entire t of the following electronic submission of the sequence listing via the USPTO EFS-WEB server, as authorized and set forth in MPEP §l730 II.B.2(a)(C), is incorporated herein by reference in its entirety for all purposes. The sequence listing is identified on the electronically filed text file as follows: Size (bytes) 246102008540Seqlist February 29, 2012 65,102 bytes FIELD This disclosure is in the field of extracellular enzymes, extracellular matrix enzymes, ses and immunology.

BACKGROUND Matrix metalloproteinases (MMPs) belong to a family of extracellular enzymes involved in forming and remodeling the ellular matrix. These enzymes contain a ved catalytic domain in which a zinc atom is coordinated by three histidine es. Over members of this family are known, organized into a number of groups including collagenases, gelatinases, stromelysins, matrilysins, enamelysins and membrane MMPs.

MMP2 and MMP9 belong to the gelatinase group of matrix metalloproteinases.

Besides containing signal peptide, propeptide, catalytic, inding and heamopexin-like domains common to most MMPs, the gelatinases also contain a plurality of fibronectin-like s and an O-glycosylated domain.

MMPs are associated with a number of diseases. However, available inhibitors of MMPs have been unsuccessful, in part due to toxicity and lack of efficacy. Therefore, there is a need for specific and effective MMP inhibitors.

The present disclosure es compositions and methods of use ing binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to matrix metalloproteinase-9 (MMP9) protein (also known as gelatinase-B). The binding proteins typically are antibodies or fragments (e. g., antigen-binding fragments) thereof and lly contain an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof). The heavy chain is typically an IgG, typically a human IgG, such as an IgGl or IgG4, or other IgG such as an IgG2, or modified version thereof. The light chain typically is a kappa chain.

Among the MMP9 binding proteins, e.g., antibodies, are those that bind specifically to MMP9 and not to other matrix oproteinases. Such MMP9 binding proteins find use in applications in which it is necessary or desirable to obtain specific modulation (e. g., tion) of MMP9, e.g., without directly ing the ty of other matrix metalloproteinases. Thus, in certain embodiments of the present disclosure an anti-MMP9 antibody or fragment thereof is a specific inhibitor of the activity of MMP9. In some aspects, the MMP9 binding ns disclosed herein will be useful for inhibition of MMP9 while allowing normal on of other, related matrix metalloproteinases.

The antibodies and nts can be bed with reference to their amino acid sequences or portions thereof, and/or various functions such as binding specificity to MMP9 or particular epitopes thereof or the ability to compete for binding to epitopes on MMP9 with particular antibodies, and/or activity, such as the ability to inhibit MMP9, e. g., non- competitively.

The antibodies and fragments include those having a heavy chain variable (VH) region having a heavy chain complementary determining region (CDR) with an amino acid sequence of SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; those having a light chain variable (VL) region having a light chain mentary ining region (CDR) with an amino acid sequence of SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18. Exemplary antibodies and fragments include those having a heavy chain CDRl with the amino acid sequence of SEQ ID NO: 13, a heavy chain CDR2 with the amino acid sequence of SEQ ID NO: 14, and a heavy chain CDR3 with the amino acid sequence of SEQ ID NO: 15, and those having a heavy chain CDR3 of SEQ ID NO: 15. Exemplary antibodies and fragments further include those with a light chain CDRl with the amino acid sequence of SEQ ID NO: 16, a light chain CDR2 with the amino acid sequence of SEQ ID NO: 17, and a light chain CDR3 with the amino acid sequence of SEQ ID NO: 18, and those having a light chain CDR3 with the amino acid sequence of SEQ ID NO: 18, as well as those having heavy chain CDRs of SEQ ID NOs: 13, 14, and 15, and light chain CDRs of SEQ ID NOs: 16, 17, and 18.

Exemplary antibodies and fragments further include those having a heavy chain CDRl with the amino acid sequence of SEQ ID NO: 34, a heavy chain CDR2 with the amino acid sequence of SEQ ID NO: 35, and a heavy chain CDR3 with the amino acid sequence of SEQ ID NO: 36, those with a heavy chain CDR3 with the amino acid sequence of SEQ ID NO: 36, those with a light chain CDRl with the amino acid sequence of SEQ ID NO: 37, a light chain CDR2 with the amino acid sequence of SEQ ID NO: 38, and a light chain CDR3 with the amino acid sequence of SEQ ID NO: 39, those with a light chain CDR3 with the amino acid sequence of SEQ ID NO: 39, as well as those having heavy chain CDRs of SEQ ID NOs: 34, 35, and 36, and light chain CDRs of SEQ ID NOs: 37, 38, and 39. ary antibodies and fragments further include those having a light chain CDRl with the amino acid sequence of SEQ ID NO: 42, a light chain CDR2 with the amino acid sequence of SEQ ID NO: 43, and a light chain CDR3 with the amino acid sequence of SEQ ID NO: 44, and those with a light chain CDR3 with the amino acid sequence of SEQ ID NO: 44.

The dies and fragments further include those having a VH region with an amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8, and those having a VL region with an amino acid sequence set forth in SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12, as well as antibodies and fragments having a VH region with an amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8 and a VL region with an amino acid sequence set forth in SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12. In a particular example, the antibodies or fragments have a VH region of SEQ ID NO: 7 and a VL region of SEQ ID NO: 12, or at least at or about 75 %, 80 %, 85 %, 90 %, 9l %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity with such sequences. They further include those having a VH region with an amino acid sequence set forth in SEQ ID NO: 32 or 47, and those with a VL region with an amino acid sequence set forth in SEQ ID NO: 33 or in SEQ ID NO: 41 or in SEQ ID NO: 48, and combinations f, and sequence having at least at or about 75 %, 80 %, 85 %, 90 %, 9l %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity with such sequences.

The antibodies and fragments r include those having a VH region with an amino acid ce set forth in SEQ ID NO: 1, and/or having a VL region with an amino acid sequence set forth in SEQ ID NO: 2, and/or a VH or VL region having at least at or about 75 %, 80 %, 85 %, 90 %, 9l %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity with such sequences.

In some cases, the heavy chain is encoded by a polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 19-22 and the light chain is encoded by a polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 23-26.

In some embodiments, the antibodies or fragments f inhibit the tic activity of MMP9, such as by non-competitive inhibition.

The antibodies and fragments further include those that specifically bind to a given epitope of MMP9. In some cases, the epitope is an epitope specifically bound by any of the above-described antibodies. In one example, the epitope contains an amino acid residue (i.e., one or more amino acid residue(s)) outside of cysteine-switch active pocket of SEQ ID NO: 27.

In certain examples, the epitope includes an amino acid residue (i.e., one or more amino acid residue(s)) within a given region of MMP9, for example, where the region is residues 104-202 of SEQ ID NO: 27. In some examples, the epitope includes an amino acid residue (i.e., one or more amino acid residue(s)) within a given region of MMP9, for example, where the region is residues 104-119, residues 159-166, or residues 191-202 of SEQ ID NO: 27. In one example, the epitope includes an amino acid residue (i.e., one or more amino acid residue) within a region of MMP9 that is es 104-119 of SEQ ID NO: 27, an amino acid residue within a region of MMP9 that is residues 159-166 of SEQ ID NO: 27, and an amino acid residue within a region of MMP9 that is residues 191-202 of SEQ ID NO: 27. In some cases, the epitope includes E111, D113, R162, or 1198 of SEQ ID NO: 27. In some cases, it includes R162 of SEQ ID NO: 27. In some cases, it includes E111, D113, R162, and 1198 of SEQ ID NO: 27.

In some cases, the antibody or fragment is human or is humanized.

In some examples, the antibodies and nts specifically bind to human MMP9 with a dissociation constant (Kd) equal to or lower than 100 nM, ally lower than 10 nM, optionally lower than 1 nM, optionally lower than 0.5 nM, optionally lower than 0.1 nM, ally lower than 0.01 nM, or optionally lower than 0.005 nM, in certain examples, between 0.1 and 0.2 nM, or n 0.1 and 10 pM, e.g., between 0.4 and 9 pm, such as between 0.4 and 8.8 pm, in the form of monoclonal antibody, scFv, Fab, or other form of antibody measured at a temperature of about 4°C, 25°C, 37°C or 42°C.

Also among the provided antibodies and fragments are those having at least at or about 75 %, 80 %, 85 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more ce identity with any of the above-described antibodies or containing various portions with at least at or about 75 %, 80 %, 85 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity with the respective portions of the antibodies described above, such as having a VH region with such identity with SEQ ID NO: 7 and a VL region with such identity with SEQ ID NO: 12. Also ed are antibodies that compete for binding to MMP9 with any of the above-described dies, such as those that compete for binding to MMP9 with an antibody having a VH region with the amino acid sequence set forth in SEQ ID NO: 7 and a VL region with the amino acid sequence set forth in SEQ ID NO: 12.

Also provided are isolated nucleic acids encoding the antibodies and fragments, such as c acids including a coding sequence for any of the described antibodies and fragments. Among the provided nucleic acids are those containing a nucleotide sequence encoding a heavy chain polypeptide comprising CDRs with the amino acid sequences set forth in SEQ ID NOs: 13-15, and/or a light chain polypeptide comprising CDRs with the amino acid ces set forth in SEQ ID NOs: 16-18. In one example, the nucleotide sequence encodes the heavy chain polypeptide, which has an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, and 5-8. In another example, the nucleotide sequence encodes the light chain polypeptide, which has an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, and 9-12. In one example, the tide sequence includes a sequence selected from the group consisting of SEQ ID NOs: 19-26, such as SEQ ID NO: 21, SEQ ID NO: 26, or SEQ ID NOs: 21 and 26. Also provided are vectors ning such nucleic acids and cells ing the same, such as host cells.

Also provided are pharmaceutical compositions ing the antibodies, fragments, nucleic acids, vectors, and cells. In some examples, the pharmaceutical itions further include a carrier or excipient, such as a pharmaceutically acceptable or ically acceptable carrier or excipient. In some cases, the pharmaceutical compositions are used in the provided therapeutic methods and uses.

Also provided are methods and uses of the antibodies, fragments, nucleic acids, vectors, cells, and compositions, for example in therapeutics, such as inhibiting MMP9 in a subject, and diagnostics, such as for detecting MMP9 in the t.

For example, provided are stic and prognostic methods involving detection of MMP9, and agents (such as any of the above-described anti-MMP9 antibodies and other MMP9 binding ns) for use in such methods. In some cases, the diagnostic method detects MMP9 expression in a test sample from a subject. Such methods can be carried out, for example, by contacting the test sample with an antibody or fragment as described herein (such as any of the above-described antibodies or fragments) and detecting binding of the antibody or fragment to protein in the sample, thereby detecting the presence of MMP9. In some cases, a sample is first obtained or ed. In some es, the methods include comparing the amount or level of MMP9 detected to a control level or amount, such as by comparing the amount of binding detected in the test sample with an amount of binding of the antibody or fragment to a control . In some cases, the methods involve simply comparing a test level and a control level of MMP9. In some cases, a higher test level (as compared to the control level) is indicative of the disease or condition.

In some cases, the MMP9 detected by the method tes the presence of a disease or condition in the subject, such as an MMP9-associated disease or condition. In some cases, the methods further include ng the subject or adjusting (i.e., altering or discontinuing) ent of the subject based on the results of the method, e. g., based on the levels of MMP9 detected in the . Among the biological samples are tissue, cells isolated from such tissues, and the like. In some cases, the methods are performed on liquid samples, such as blood, plasma, serum, whole blood, saliva, urine, or semen. Tissue samples include, for example, formalin-fixed or frozen tissue ns.

Also provided are methods of inhibiting MMP9 activity in a subject and/or treating a disease or ion in the subject, for example, using an agent that non-competitively inhibits MMP9, and agents (such as any of the described anti-MMP9 antibodies and other MMP9 binding proteins) for use in such methods. The s generally are carried out by administering to the subject an MMP9 binding protein, such as an MMP9-binding antibody or fragment thereof as provided herein, e.g., in an effective amount. The antibody or fragment generally specifically binds to and non-competitively inhibits MMP9, for example, such that MMP9 activity is inhibited in the subject. In some cases, the antibody or fragment is one that binds MMP9 outside of the cysteine-switch active pocket, such as in one of the epitopes described above. In some cases, the antibody or fragment does not substantially bind to an MMP protein other than MMP9 and/or does not substantially bind to MMP2.

The subject generally is one with a disease or condition, typically one associated with increased or decreased MMP9 expression and/or activity. In certain cases, the subject with a disease or condition associated with increased MMP9 sion and/or activity. In other cases, the subject with a disease or condition associated with decreased MMP9 expression and/or activity.

Also provided are MMP9 ptides, including mutant MMP9 ptides, such as those containing residues 8 of SEQ ID NO: 27, and those having an amino acid sequence containing residues 111-198 of SEQ ID NO: 27 with an amino acid substitution at residue 111, 113, 162, or 198 of SEQ ID NO 27, or with an amino acid substitution at all such residues.

Also ed are uses of any of the above-described antibodies, nucleic acids, vectors, cells, and compositions, in the therapeutic and diagnostic methods described above.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the amino acid sequence of the heavy chain variable region of a mouse monoclonal anti-MMP9 antibody (AB0041), along with the amino acid sequences of humanized ts of heavy chain (VH1-VH4), aligned to show differences in framework amino acid sequence ing from humanization. CDRs are shown in italics, and amino acids that are different in the humanized variants, ed to the parent mouse monoclonal, are underlined.

Figure 2 shows the amino acid sequence of the light chain variable region of a mouse monoclonal anti-MMP9 antibody (AB0041), along with the amino acid sequences of zed variants of this light chain (VHl-VH4), aligned to show differences in framework amino acid sequence resulting from humanization. CDRs are shown in italics, and amino acids that are different in the humanized variants, compared to the parent mouse monoclonal, are underlined.

Figure 3 shows a schematic diagram of the MMP9 protein.

Figure 4 shows a comparison between the amino acid sequences of the heavy and light chains of antibodies ated AB004l, M4, and M12.

DETAILED DESCRIPTION Practice of the present disclosure employs, unless otherwise indicated, standard methods and conventional techniques in the fields of cell y, toxicology, molecular biology, biochemistry, cell culture, immunology, oncology, recombinant DNA and related fields as are within the skill of the art. Such techniques are described in the ture and thereby available to those of skill in the art. See, for e, Alberts, B. et al., “Molecular Biology of the Cell,” 5th edition, Garland Science, New York, NY, 2008; Voet, D. et a1. “Fundamentals of mistry: Life at the Molecular level,” 3rd edition, John Wiley & Sons, Hoboken, NJ, 2008; Sambrook, J. et al., “Molecular Cloning: A Laboratory Manual,” 3rel edition, Cold Spring Harbor Laboratory Press, 2001; Ausubel, F. et (11., “Current Protocols in Molecular y,” John Wiley & Sons, New York, 1987 and periodic updates; Freshney, R.I., “Culture of Animal Cells: A Manual of Basic Technique,” 4th edition, John Wiley & Sons, Somerset, NJ, 2000; and the series ds in logy,” Academic Press, San Diego, CA. See also, for e, “Current Protocols in Immunology,” (R. Coico, series editor), Wiley, last updated August 2010.

Certain MMPs play roles in tumor growth, metastasis, inflammation, autoimmunity, and vascular disease. See, for e, Hu et al. (2007) Nature Reviews: Drug Discovery 6:480-498. Thus, it is desirable to inhibit the activity of one or more particular MMPs in certain therapeutic settings. While g significant homology at a sequence level, the expression and onal roles of the two gelatinases MMP9 and MMP2 vary significantly. MMP9 expression is induced by a number of disease associated cytokines and growth factors. Also, the MMP9 knockout mouse is protected in a variety of disease models, whereas MMP2 is more constitutively expressed and the MMP2 knockout animals tend toward little protection. Some studies have shown that MMP2 knockout mouse exhibited worse disease in challenge models.

For some es or disorders, the ty of more than one MMPs is inhibited. In clinical studies, the inhibitors to more than one MMPs have caused adverse effects, such as toxicity or lack of efficacy, that are not desired. It has been shown that the activity of certain MMPs, e.g., MMP2, is often required for normal tissue tasis and/or is protective against disease. n available MMP inhibitors have caused side effects.

Among the provided embodiments are agents, including therapeutic reagents, such as dies and antigen-binding fragments thereof, that specifically inhibit the catalytic activity of a single MMP or a select plurality of MMPs, such as MMP9 and that do not react with or inhibit certain other MMPs or any other MMPs. Also among the provided embodiments are s and uses of the same for treatment of s diseases.

MMP9 Binding ns The present disclosure provides binding proteins, e. g., antibodies and fragments (e. g., antigen-binding fragments) thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), e.g., human MMP9, such as the human MMP9 having an amino acid sequence set forth in SEQ ID NO: 27 or SEQ ID NO: 28. The binding proteins of the present disclosure generally comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional nt thereof).

The disclosure further provides MMP9 binding proteins that bind specifically to MMP9 and not to other matrix metalloproteinases such as MMPl, MMP2, MMP3, MMP7, MMP9, MMPlO, MMP12, and MMPl3. Such ic MMP9 binding proteins are thus generally not significantly or detectably crossreactive with non-MMP9 matrix metalloproteinases. MMP9 binding proteins that specifically bind MMP9 find use in applications in which it is necessary or desirable to obtain specific modulation (e. g., inhibition) of MMP9, e.g., without directly affecting the activity of other matrix metalloproteinases.

In n embodiments of the t disclosure, an anti-MMP9 antibody is an inhibitor of the ty of MMP9, and can be a specific inhibitor of MMP9. In one embodiment, the MMP9 binding proteins disclosed herein is useful for inhibition of MMP9 while not affecting other matrix metalloproteinases. "An inhibitor of MMP” or “inhibitor of MMP9 activity" can be an antibody or an n binding fragment thereof that directly or indirectly inhibits activity of MMP9, including but not limited to enzymatic processing, ting action of MMP9 on it substrate (e. g., by inhibiting substrate g, substrate cleavage, and the like), and the like.

The present sure also provides MMP9 binding proteins that specifically bind to non-mouse MMP9, such as human MMP9, Cynomolgus monkey MMP9, and rat MMP9.

The present disclosure also provides MMP9 g proteins (e.g., anti-MMP9 antibodies and functional fragments f) that act as non-competitive inhibitors. A “non- competitive inhibitor” refers to an inhibitor binds at site away from substrate binding site of an enzyme, and thus can bind the enzyme and effect inhibitory activity less of r or not the enzyme is bound to its substrate. The non-competitive or allosteric inhibition is generally independent of substrate association or concentration. Such non-competitive inhibitors can, for example, provide for a level of inhibition that can be substantially independent of substrate concentration.

MMP9 binding proteins (e.g., dies and onal fragments thereof) of the present sure include those that bind MMP9, particularly human MMP9, and having a heavy chain polypeptide (or functional fragment thereof) that has at least about 80%, 85%, 90%, 95% or more amino acid sequence identity to a heavy chain polypeptide disclosed herein.

MMP9 binding proteins (e.g., antibodies and functional nts thereof) of the t disclosure include those that bind MMP9, particularly human MMP9, and having a light polypeptide (or functional fragment thereof) that has at least about 80%, 85%, 90%, 95% or more amino acid sequence ty to a heavy chain polypeptide disclosed .

MMP9 binding proteins (e.g., antibodies and functional fragments thereof) of the present disclosure include those that bind MMP9, particularly human MMP9, and have a heavy chain polypeptide (or functional fragment thereof) having the complementarity determining regions (“CDRs”) of heavy chain polypeptide and the CDRs of a light chain polypeptide (or functional fragment thereof) as disclosed . ogy” or “identity” or “similarity” as used herein in the context of nucleic acids and polypeptides refers to the relationship between two polypeptides or two nucleic acid molecules based on an alignment of the amino acid sequences or nucleic acid sequences, respectively. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of ison. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position; when the equivalent site occupied by the same or a similar amino acid residue (e. g., similar in steric and/or onic nature), then the molecules can be referred to as homologous (similar) at that position. Expression as a percentage of homology/similarity or identity refers to a function of the number of identical or similar amino acids at positions shared by the ed sequences. In comparing two sequences, the absence of residues (amino acids or nucleic acids) or presence of extra residues also decreases the identity and homology/similarity.

As used herein, “identity” means the tage of identical nucleotide or amino acid residues at corresponding ons in two or more sequences when the sequences are aligned to maximize sequence matching, i.e., taking into account gaps and insertions. Sequences are lly aligned for maximum correspondence over a designated region, e. g., a region at least about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or more amino acids or nucleotides in length, and can be up to the full-length of the reference amino acid or nucleotide. For ce comparison, typically one ce acts as a reference sequence, to which test sequences are compared.

When using a sequence comparison thm, test and reference sequences are input into a computer program, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the ated program parameters.

Examples of algorithms that are suitable for determining percent sequence identity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol.

Biol. 215: 403-410 and Altschul et al. (1977) Nucleic Acids Res. 25: 3389-3402, respectively.

Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). r exemplary algorithms e ClustalW (Higgins D., et al. (1994) Nucleic Acids Res 22: 4673-4680), available at www.ebi.ac.uk/Tools/clustalw/index.html. e positions which are not identical can differ by vative amino acid substitutions. Conservative amino acid substitutions refer to the hangeability of residues having similar side . For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatichydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and nine.

Sequence identity between two nucleic acids can also be described in terms of hybridization of two molecules to each other under stringent conditions. The hybridization conditions are selected following standard methods in the art (see, for example, Sambrook, et al., Molecular g: A Laboratory Manual, Second Edition, (1989) Cold Spring Harbor, NY).

An example of stringent hybridization conditions is hybridization at 500C or higher and 0.1 x SSC (15 mM sodium chloride/1.5 mM sodium citrate). Another example of stringent hybridization conditions is overnight incubation at 42 0C in a solution: 50 % formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5 x Denhardt’s solution, 10% dextran sulfate, and 20 mg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1 x SSC at about 65 0C. Stringent hybridization conditions are ization conditions that are at least as stringent as the above representative conditions, where conditions are considered to be at least as stringent if they are at least about 80% as stringent, typically at least 90% as stringent as the above specific stringent conditions. ingly, the present disclosure provides, for example, antibodies or antigen g fragments thereof, comprising a heavy chain variable region polypeptide having at least 80%, 85%, 90%, 95%, or greater amino acid sequence identity to an amino acid sequence of a heavy chain variable region described herein (e. g., SEQ ID NOS:1 or 5-8), and a variable light chain polypeptide having at least 80%, 85%, 90%, 95%, or greater amino acid sequence ty to an amino acid sequence of a light chain polypeptide as set forth herein (e.g., SEQ ID NOS:2 or 9-12).

Examples of anti-MMP9 antibodies of the present disclosure are described in more detail below.

Antibodies The MMP9 binding ns include antibodies and functional fragments thereof, such as those that specifically bind to MMP9. As used herein, the term "antibody" means an isolated or recombinant polypeptide binding agent that comprises peptide ces (e. g., variable region sequences) that specifically bind an antigenic e. The term is used in its broadest sense and specifically covers monoclonal antibodies (including full-length monoclonal antibodies), onal antibodies, human dies, humanized antibodies, chimeric antibodies, dies, diabodies, multispecific dies (e.g., bispecific antibodies), and antibody fragments including but not limited to Fv, scFv, Fab, Fab' F(ab')2 and Fabz, so long as they exhibit the desired biological activity. The term “human antibody” refers to antibodies containing sequences of human origin, except for possible non-human CDR regions, and does not imply that the full ure of an immunoglobulin molecule be present, only that the antibody has minimal immunogenic effect in a human (i.e., does not induce the production of antibodies to itself).

An "antibody fragment" comprises a portion of a full-length antibody, for example, the antigen g or le region of a full-length antibody. Such antibody fragments may also be referred to herein as “functional fragments: or “antigen-binding fragments”. Examples of antibody fragments include Fab, Fab‘, F(ab')2, and Fv fragments; diabodies; linear antibodies (Zapata et a1. (1995) Protein Eng. 8(10):1057-1062); single-chain dy molecules; and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" nts, each with a single n-binding site, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. Pepsin ent yields an F(ab')2 nt that has two antigen combining sites and is still capable of cross-linking antigen.

"Fv" is a minimum antibody fragment containing a te antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this uration that the three complementarity- determining regions (CDRs) of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or an isolated VH or VL region comprising only three of the six CDRs specific for an antigen) has the ability to recognize and bind antigen, although generally at a lower affinity than does the entire FV fragment.

The “Fab” fragment also contains, in on to heavy and light chain variable regions, the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments were originally observed following papain digestion of an antibody. Fab' fragments differ from Fab fragments in that F(ab‘) fragments contain several additional residues at the carboxy terminus of the heavy chain CH1 domain, including one or more cysteines from the antibody hinge region. F(ab')2 fragments contain two Fab fragments joined, near the hinge region, by disulfide bonds, and were originally observed ing pepsin digestion of an antibody. Fab‘-SH is the designation herein for Fab' nts in which the cysteine residue(s) of the constant s bear a free thiol group. Other chemical couplings of antibody fragments are also known.

The "light chains" of antibodies (immunoglobulins) from any vertebrate s can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to five major classes: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into sses (isotypes), e.g., IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2.

"Single-chain Fv" or "st" or "scFv" antibody fragments comprise the VH and VL domains of antibody, wherein these domains are t in a single polypeptide chain. In some ments, the Fv polypeptide further comprises a ptide linker between the VH and VL domains, which enables the st to form the desired structure for antigen g. For a review of st, see Pluckthun, in The Pharmacology ofMonoclonal Antibodies, vol. 113 (Rosenburg and Moore eds.) Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain le domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the s are forced to pair with the complementary domains of another chain, thereby creating two antigen-binding sites.

Diabodies are additionally described, for example, in EP 404,097; WO 93/11161 and Hollinger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448.

An "isolated" antibody is one that has been identified and ted and/or recovered from a component of its natural environment. Components of its natural environment may include enzymes, es, and other proteinaceous or nonproteinaceous solutes. In some ments, an isolated antibody is purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, for example, more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, e.g., by use of a ng cup sequenator, or (3) to homogeneity by gel electrophoresis (e. g., SDS- PAGE) under reducing or nonreducing conditions, with detection by Coomassie blue or silver stain. The term "isolated antibody" includes an dy in situ within recombinant cells, since at least one component of the antibody's natural environment will not be present. In certain embodiments, ed antibody is prepared by at least one purification step.

As used herein, “immunoreactive” refers to antibodies or fragments thereof that are specific to a sequence of amino acid residues (“binding site” or “epitope”), yet if are cross- reactive to other peptides/proteins, are not toxic at the levels at which they are formulated for administration to human use. "Epitope" refers to that portion of an antigen capable of forming a binding interaction with an antibody or antigen binding fragment f. An epitope can be a linear peptide sequence (i.e., “continuous”) or can be composed of noncontiguous amino acid sequences (i.e., “conformational” or “discontinuous”). The term “preferentially binds” means that the binding agent binds to the binding site with greater affinity than it binds unrelated amino acid ces.

Anti-MMP9 antibodies can be described in terms of the CDRs of the heavy and light chains. As used herein, the term "CDR" or "complementarity ining region" is ed to mean the non-contiguous n combining sites found within the variable region of both heavy and light chain ptides. These particular regions have been described by Kabat et al., J.

Biol. Chem. 252:6609-6616 ; Kabat et al., US. Dept. of Health and Human Services, "Sequences of proteins of immunological interest" (1991); by Chothia et al., J. Mol. Biol. 196:901-917 ; and lum et al., J. Mol. Biol. 262:732-745 (1996), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either tion to refer to a CDR of an antibody or grafted antibodies or variants thereof is ed to be within the scope of the term as defined and used herein. The amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth below in Table l as a comparison.

Table 1: CDR Definitions Kabatl Chothiaz lum3 vH CDRl 31—35 26—32 30—35 vH CDR2 50—65 53—55 47—58 vH CDR3 95—102 96—101 93—101 vL CDRl 24—34 26—32 30—36 vL CDR2 50—56 50—52 46—55 vL CDR3 89—97 91—96 89—96 1Residue numbering follows the nomenclature of Kabat et al., supra 2Residue numbering follows the nomenclature of Chothia et al., supra 3Residue numbering follows the nomenclature of MacCallum et al., supra As used herein, the term "framework" when used in reference to an antibody le region is intended to mean all amino acid residues outside the CDR regions within the variable region of an antibody. A variable region framework is generally a discontinuous amino acid sequence between about 0 amino acids in length but is intended to reference only those amino acids e of the CDRs. As used herein, the term "framework region" is intended to mean each domain of the ork that is separated by the CDRs.

In some ments, an antibody is a zed antibody or a human antibody.

Humanized antibodies include human immununoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient are ed by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. Thus, humanized forms of non-human (e.g., murine) antibodies are ic immunoglobulins which contain minimal sequence derived from non- human immunoglobulin. The non-human sequences are located primarily in the variable regions, ularly in the complementarity-determining regions . In some embodiments, Fv ork residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDRs correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. For the purposes of the present disclosure, humanized antibodies can also include immunoglobulin fragments, such as Fv, Fab, Fab‘, F(ab')2 or other n-binding subsequences of antibodies.

The humanized dy can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. See, for e, Jones et al. (1986) Nature 321:522-525; Riechmann et al. (1988) Nature 332:323-329; and Presta (1992) Curr. 0p. Struct. Biol. 2:593-596.

Methods for humanizing man antibodies are known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" or “donor” residues, which are typically ed from an "import" or “donor” variable domain. For e, humanization can be performed essentially according to the method of Winter and co- workers rodent CDRs or CDR sequences for the corresponding sequences of a , by tuting human antibody. See, for example, Jones et al., supra; Riechmann et al., supra and Verhoeyen et al. (1988) Science 239:1534-1536. Accordingly, such "humanized" antibodies include chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.

In certain embodiments, humanized antibodies are human antibodies in which some CDR residues and optionally some framework region residues are substituted by residues from analogous sites in rodent antibodies (e. g., murine monoclonal antibodies).

Human antibodies can also be produced, for example, by using phage display libraries. Hoogenboom et al. (1991) J. Mol. Biol, 227:381; Marks et al. (1991) J. Mol. Biol. 1. Other methods for preparing human monoclonal antibodies are described by Cole et al. (1985) “Monoclonal Antibodies and Cancer Therapy,” Alan R. Liss, p. 77 and Boemer et al. (1991) J. Immunol. 147:86-95.

Human antibodies can be made by introducing human immunoglobulin loci into transgenic animals (e. g., mice) in which the endogenous immunoglobulin genes have been partially or completely vated. Upon immunological challenge, human antibody production is observed, which closely resembles that seen in humans in all ts, including gene rearrangement, assembly, and antibody repertoire. This approach is bed, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the ing scientific publications: Marks et al. (1992) chnology 10:779-783 (1992); Lonberg et al. (1994) Nature 368: 856-859; Morrison (1994) Nature 368:812-813; Fishwald et al. (1996) Nature Biotechnology 14:845-851; Neuberger (1996) Nature Biotechnology 14:826; and g et al. (1995) . Rev. Immunol. 13:65-93.

Antibodies can be affinity matured using known selection and/or mutagenesis methods as described above. In some embodiments, affinity matured antibodies have an affinity which is five times or more, ten times or more, twenty times or more, or thirty times or more than that of the starting antibody (generally , rabbit, chicken, humanized or human) from which the matured antibody is prepared.

An antibody can also be a ific dy. Bispecific antibodies are monoclonal, and may be human or humanized dies that have binding specificities for at least two different antigens. In the present case, the two different binding icities can be directed to two different MMPs, or to two different epitopes on a single MMP (e. g., MMP9).

An dy as disclosed herein can also be an immunoconjugate. Such conjugates comprise an antibody (e.g., to MMP9) conjugated to a second molecule, such as a reporter An immunoconjugate can also comprise an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, a toxin (e. g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive e (i.e., a radioconjugate).

An antibody that “specifically binds to” or is “specific for” a particular polypeptide or an epitope refers to the ive binding of the antibody to the target antigen or epitope; these terms, and methods for determining specific binding, are well understood in the art. An antibody exhibits “specific g” for a particular target antigen or epitope if it binds with greater affinity, avidity, more readily, and/or with greater duration to that target n or epitope than it does with other substances. In some embodiments, the antibody that specifically binds to the polypeptide or epitope is one that that binds to that particular polypeptide or epitope without substantially g to any other polypeptide or polypeptide epitope.

In some embodiments, the provided antibodies specifically bind to human MMP9 with a dissociation constant (Kd) equal to or lower than 100 nM, optionally lower than 10 nM, optionally lower than 1 nM, optionally lower than 0.5 nM, ally lower than 0.1 nM, optionally lower than 0.01 nM, or optionally lower than 0.005 nM, in certain examples, between 0.1 and 0.2 nM, or between 0.1 and 10 pM, e.g., between 0.4 and 9 pm, such as between 0.4 and 8.8 pm, in the form of monoclonal antibody, scFv, Fab, or other form of antibody measured at a temperature of about 4°C, 25°C, 37°C or 42°C.

In certain ments, an antibody of the present disclosure binds to one or more processing sites (e.g., sites of proteolytic cleavage) in MMP9, thereby effectively blocking processing of the proenzyme or preproenzyme to the catalytically active enzyme, and thus reducing the proteolytic activity of the MMP9.

In certain embodiments, an antibody according to the present disclosure binds to MMP9 with an affinity at least 2 times, at least 5 times, at least 10 times, at least 25 times, at least 50 times, at least 100 times, at least 500 times, or at least 1000 times greater than its binding affinity for another MMP. Binding affinity can be measured by any method known in the art and can be expressed as, for e, on-rate, off-rate, dissociation constant (Kd), brium constant (Keg) or any term in the art.

In n embodiments, an dy according to the present disclosure is one that inhibits the enzymatic (i.e., catalytic) activity of MMP9, such as a non-competitive inhibitor of the tic activity of MMP9. In certain embodiments, an antibody according to the present disclosure binds Within the catalytic domain of MMP9. In additional ments, an antibody according to the present disclosure binds outside the catalytic domain of MMP9.

Also provided are antibodies or antigen binding fragments thereof that compete with any one or more of the MP9 antibodies or antigen binding fragments thereof described herein for binding to MMP9. Thus, the t disclosure contemplates anti-MMP9 antibodies, and functional nts thereof, that compete for binding with, for example, an antibody having a heavy chain polypeptide of any of SEQ ID NOS: 1 or 5-8, a light chain polypeptide of SEQ ID NOS: 2 or 9-12, or combinations thereof. In one embodiment, the MP9 dy, or functional fragment thereof, competes for binding to human MMP9 with the antibody described herein as AB004l.

Epitope Binding Also provided are antibodies and fragments thereof that bind to the same e, e. g., MMP9 epitope as any one or more of the antibodies described herein. Also provided are antibodies and fragments that ically bind to an epitope of MMP9, Where the epitope includes an amino acid residue Within a particular region of MMP9 or multiple regions of MMP9. Such regions can e, for e, structural loops and/or other structural domains of MMP9, such as those shown to be important for binding to exemplary dies described herein. Typically, the regions are defined according to amino acid residue positions on the full- length MMP9 sequence, e.g., SEQ ID NO: 27. In some examples, the epitope is outside of cysteine-switch active pocket of SEQ ID NO: 27. In some example, the epitope contains an amino acid residue (i.e., one or more amino acid residue(s)) Within a region that is residues 104- 202 of SEQ ID NO: 27. In one example, the epitope contains an amino acid residue (i.e., one or more amino acid residue(s)) Within a region that is residues 104-119, residues 159-166, or residues 191-202 of SEQ ID NO: 27. In some aspects, the epitope includes an amino acid residue (i.e., one or more amino acid residue(s)) Within a region of MMP9 that is residues 104- 119 of SEQ ID NO: 27, an an amino acid e within a region of MMP9 that is residues 159- 166 of SEQ ID NO: 27, and an amino acid residue within a region of MMP9 that is es 191-202 of SEQ ID NO: 27. In some cases, the epitope includes E111, D113, R162, or 1198 of SEQ ID NO: 27. In some cases, it includes R162 of SEQ ID NO: 27. In some cases, it includes E111, D113, R162, and 1198 of SEQ ID NO: 27.

MMP9 sequence The amino acid sequence of human MMP9 protein is as follows: MSIWQPLVIV IIVIGCCFAA PQQRQSTIV. FPGDIQTNIT DRQLAfiflYLY 50 RYGY.?VAflM RGfiSKSIGPA IILIQKQIS. PfliGfiuDSA_ LKAMRTPRCG 100 VPDEGREQ_E flGDIKW{HHN ITYWIQNYS? DIPRAVIDDA FARAFAEWSA 150 VTPETFTRVY SQDADIVIQF GVAEiGDGYP FDGKDGELAH AFPPGPGIQG 200 DAiFDDD?.W SIG<GVVVPT RFGVADGAAC HFPFIFEGRS YSACTTDGRS 250 DGEPWCSI_A VYDIDDREGE CPSLRLYIRD GVADGKPCQF PFIFQGQSYS 300 ACTTDGRS 3G 'TTAVY DRD (JFGFCP TVMGG NSAG'I‘. .CVFP 350 bibLG<LYSi GDGR EWCATTSNFD FCPD QGYSIFIVAA ~00 H?FGHA.G.D {SSVP?A. Y P Y?b_fiGPP .{KDDVNGIR HLYGPRPflPfl ~50 HUF'IO'U'URPP__11PQ P_APP_VCPI GPPIViPSL? PIAGP_GPPS PTAG 500 SIA__VPDS VVWI FDAIAEIGVQ GKYW RFSEGRGSQP 550 GPFLIAD<W PALPR<IDSV b*flP.S<K.F FFSGRQVWVY TGASVEGPQQ 600 DKLGEGADV AQVTGAERSG RG<MIIFSGQ RLWRFDVKAQ MVDPRSASEV 650 RMFPGVPDD THDVFQYREK AYFCQDQFYW RVSSRSELNQ VDQVGYVTYD 700 .QCPflD (SfiQ ID WO:27) Protein domains are shown schematically in Figure 3 and are indicated below: Amino Acid # Feature 1-19 Signal Peptide 38-98 Peptidoglycan Binding Domain R98/C99 Cysteine-switch active pocket 112-445 Zn dependent metalloproteinase domain 223-271 Fibronectin type II domain (gelatin binding ) 281-329 Fibronectin type II domain (gelatin binding domain) 8 Fibronectin type II domain (gelatin binding domain) 1 Zn binding region 521-565 Hemopexin-like domain 567-608 Hemopexin-like domain 613-659 Hemopexin-like domain 661-704 Hemopexin-like domain The amino acid ce of mature full-length human MMP9 (which is the amino acid sequence of the propolypeptide of SEQ ID NO:27 t the signal peptide) is: APQQQQSTLVL FPGDIQTNLT DRQIAfifiYLY RYGYIQVAflM RGfiSKSLGPA I..QKQLS. PfiiGfiuDSAI LKAMQTPQCG VPDEGREQ_E fiGDIKWHHHN ITYWIQNYS? DIPRAVIDDA FARAFAEWSA VTPETFTRVY SRDADIVIQF GVAEiGDGYP FDGKDGELAH AFPPGPGIQG DAHFDDDEIW SIG<GVVVPT QFGVADGAAC HFPFIFEGRS YSACTTDGRS DGLPWCST"A_ VYDTDDRFGF ' GWADGKPCQF PFIFQGQSYS ACTTDGRSDG YRWCATTAWY TRADSTVMGG NSAGfiICVEP LYSI C_SLG?GDGR S DKKWGFCPD QGYSIFIVAA H?FGHA.G.D { SVPQA.' Y P Y?b_fiGPP .{KDDVNGIR HLYGPRPfiPfi QPP__11PQ P .APP_VCPI GPPIViPSL? P1AGP.GPPS AGPIGPPIAG SIA__VPES WVVI F DAIA?IGVQ .YLF<DGKYW GSQP HUT‘IO'U'UGPFLIAD<W PALPR<EDSV b fifiPIS<KIF FFSGQQVWVY TGASVIGPQQ DKLGIGADV AQVTGAEQSG RG<MIIFSGQ QLWRFDVKAQ MVDPRSASEV PED THDVFQYQEK AYFCQDQFYW QVSSQSELNQ VDQVGYVTYD .QCPfiD (SfiQ ID VO:28) The amino acid sequence of the signal peptide is MSLWQPLVLV LLVLGCCFA (SEQ ID NO:29).

Also provided are MMP9 polypeptides, including mutant MMP9 polypeptides. Such peptides are useful, for example, in generating and selecting antibodies and fragments as provided herein. Exemplary polypeptides include those having an amino acid sequence ning residues 2 of SEQ ID NO: 27, and those having an amino acid sequence of SEQ ID NO: 27 with an amino acid substitution at e 111, 113, 162, or 198 of SEQ ID NO 27 or with an amino acid substitution at all such residues. Other exemplary polypeptides include those having an amino acid sequence containing residues 111-198 of SEQ ID NO: 27, and those having an amino acid sequence containing residues 111-198 of SEQ ID NO: 27 with an amino acid substitution at residue 111, 113, 162, or 198 of SEQ ID NO 27 or with an amino acid substitution at all such es. Such polypeptides find use, for example, in selecting antibodies that bind to epitopes containing such residues and/or for which such es of MMP9 are important for binding, such as those described herein.

The present sure contemplates MMP9 binding proteins that bind any portion of MMP9, e.g., human MMP9, with MMP9 binding proteins that preferentially bind MMP9 relative to other MMPs being of particular interest.

MP9 antibodies, and functional fragments thereof, can be generated ingly to methods well known in the art. ary anti-MMP9 antibodies are provided below.

Mouse monoclonal anti-MMP9 antibodies A mouse onal antibody to human MMP9 was obtained as described in Example 1. This antibody contains a mouse IgG2b heavy chain and a mouse kappa light chain, and is denoted AB0041.

The amino acid sequence of the AB0041 heavy chain is as follows: MAVLVLFLCLVAFPSCVLSQVQLKESGPGLVAPSQSLSITCTVSGFSLLSY GVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRLSISKDDSKSQVFLK MNSLQTDDTAIYYCARYYYGMDYWGQGTSVTVSSAKTTPPSVYPLAPGC GDTTGSSVTLGCLVKGYFPESVTVTWNSGSLSSSVHTFPALLQSGLYTMSSSVT VPSSTWPSQTVTCSVAHPASSTTVDKKLEPSGPISTINPCPPCKECHKCPAPNL EGGPSVFIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVRISWFVNNVEVHTA QTQTHREDYNSTIRVVSALPIQHQDWMSGKEFKCKVNNKDLPSPIERTISKIK GLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKD TAPVLDSDGSYFIYSKLDIKTSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPGK (SEQ ID NO: 1) The signal sequence is underlined, and the sequence of the IgG2b constant region is presented italics.

The amino acid sequence of theAB0041 light chain is as follows: MESS 21g FLWLSGVDGDIVMTQSHKFMSTSVGDRVSITCKASQDV YQQKTGQSPKLLIYSSSYRNTGVPDRFTGSGSGTDFTFTISSVQ AEDLAVYFCQQHYITPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASV VCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:2) The signal sequence is underlined, and the sequence of the kappa constant region is presented in italics.

The ing amino acid sequence comprises the framework regions and complementarity-determining regions (CDRs) of the variable region of the IgG2b heavy chain of AB0041 (with CDRs underlined): QVQLKESGPGLVAPSQSLSITCTVSGFSLLSYGVHWVRQPPGKGLEWLGX TNYNSALMSRLSISKDDSKSQVFLKMNSLQTDDTAIYYCARfl YGMDYWGQGTSVTVSS (SEQ ID NO:3) The following amino acid sequence comprises the ork regions and complementarity-determining regions (CDRs) of the variable region of the kappa light chain of AB004l (with CDRs underlined): DIVMTQSHKFMSTSVGDRVSITCKASS 2DVRNTVAWYQQKTGQSPKLLIY SSSYRNTGVPDRFTGSGSGTDFTPTISSVQAEDLAVYFCS 2g 2HYITPYTFGG GTKLEIK (SEQ ID NO:4) Other exemplary mouse anti-human MMP9 antibodies (e.g., M4 and M12) are described in Example 1B. An exemplary ouse MMP9 antibody (AB0046) is described in Example lC.

Other exemplary mouse anti-human MMP9 antibodies e antibodies comprise the variable regions having the ce of SEQ ID NO: 3, and the constant regions having 95% similarity as the sequences of the IgG2b constant regions. In addition, the exemplary mouse anti-human MMP9 antibodies include antibodies comprise the variable regions having the sequence of SEQ ID NO: 4, and the constant regions having 95% similarity as the sequences of the IgG2b constant regions. Other exemplary mouse anti-human MMP9 antibodies e antibodies comprise the variable regions having the sequences of SEQ ID NOs: 3 and 4, and the constant regions having 95% similarity as the sequences of the IgG2b constant regions. Such ouse dies are suitable for testing and assessing the nhibition methods.

Heavy-chain variants The amino acid sequences of the variable regions of the AB004l heavy and light chains were separately modified, by altering framework region sequences in the heavy and light chain variable regions. The effect of these sequence alterations was to deplete the antibody of human T-cell es, thereby reducing or abolishing its immunogenicity in humans.

Four heavy-chain variants were constructed, in a human IgG4 heavy chain background ning a S24lP amino acid change that stabilizes the hinge domain (Angal et al. (1993) Molec. Immunol. -108), and are denoted VHl, VH2, VH3 and VH4. The amino acid sequences of their framework regions and CDRs are as follows: QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLG VIWTGGTTNYNSALMSRLTISKDDSKSTVYLKMNSLKTEDTAIYYCARY YYGMDYWGQGTSVTVSS (SEQ ID N05) QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLG VIWTGGTTNYNSALMSRLTISKDDSKNTVYLKMNSLKTEDTAIYYCARY YYGMDYWGQGTLVTVSS (SEQ ID NO:6) SGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLG VIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARY YYGMDYWGQGTLVTVSS (SEQ ID NO:7) SGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLG VIWTGGTTNYNSALMSRFTISKDDSKNTLYLKMNSLKTEDTAIYYCARY YYGMDYWGQGTLVTVSS (SEQ ID NO:8) Figure 1 shows an alignment of the amino acid sequences of the variable s of the humanized heavy chains and indicates the differences in amino acid sequences in the framework regions among the four variants.

Light-chain variants Four light-chain variants were constructed, in a human kappa chain background, and are denoted Vkl, Vk2, Vk3 and Vk4. The amino acid sequences of their framework regions and CDRs are as follows: DIVMTQSPSFLSASVGDRVTITCKASQDVRNTVAWYQQKTGKAPKLLIYS SSYRNTGVPDRFTGSGSGTDFTLTISSLQAEDVAVYFCQQHYITPYTFGGG TKVEIK (SEQ ID NO:9) DIVMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYS SSYRNTGVPDRFTGSGSGTDFTLTISSLQAEDVAVYFCQQHYITPYTFGGG TKVEIK (SEQ ID NOilO) DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYS GVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQHYITPYTFGGG TKVEIK (SEQ ID NO:11) DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYS SSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGG GTKVEIK (SEQ ID NO:12) Figure 2 shows an alignment of the amino acid sequences of the le regions of the humanized light chains and indicates the differences in amino acid sequences in the framework regions among the four variants.

The zed heavy and light chains are combined in all possible pair-Wise ations to generate a number of functional zed anti-MMP9 antibodies. For example, provided are antibodies with a heavy chain variable (VH) region having the amino acid sequence set forth in any of SEQ ID NOs: 3, 5, 6, 7, and 8; antibodies having a light chain variable (VL) region having the amino acid sequence set forth in any of SEQ ID NOs: 4, 9, 10, 11, and 12; and antibodies with a heavy chain variable (VH) region having the amino acid sequence set forth in any of SEQ ID NOs: 3, 5, 6, 7, and 8 and a light chain variable (VL) region having the amino acid sequence set forth in any of SEQ ID NOs: 4, 9, 10, 11, and 12, as well as antibodies that compete for binding to MMP9 with such antibodies and antibodies having at least at or about 75 %, 80 %, 85 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity with such antibodies. In one example, the antibody has a VH region with an amino acid ce having at least at or about 75 %, 80 %, 85 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity with SEQ ID NO: 7 and a VL region with an amino acid sequence having at least at or about 75 %, 80 %, 85 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity with SEQ ID NO: 12, or a VH region of SEQ ID NO: 7 and a VL region of SEQ ID NO: 12.

Additional heavy chain variable region amino acid sequences having 75% or more, 80% or more, 90% or more, 95% or more, or 99% or more homology to the heavy chain variable region sequences disclosed herein are also provided. rmore, additional light chain variable region amino acid sequences having 75% or more, 80% or more, 90% or more, 95% or more, or 99% or more homology to the light chain variable region sequences disclosed herein are also provided.

Additional heavy chain variable region amino acid sequences having 75% or more, 80% or more, 90% or more, 95% or more, or 99% or more sequence identity to the heavy chain variable region sequences disclosed herein are also provided. Furthermore, additional light chain variable region amino acid sequences having 75% or more, 80% or more, 90% or more, 95% or more, or 99% or more sequence identity to the light chain variable region sequences disclosed herein are also provided.

C0mplementarity-determining regions (CDRs) In some embodiments, the CDRs of the heavy chain of exemplary provided anti- MMP9 antibodies as disclosed herein have the following amino acid sequences: CDRl: GFSLLSYGVH (SEQ ID NO:13) CDR2: VIWTGGTTNYNSALMS (SEQ ID NO:14) CDR3: YYYGMDY (SEQ ID NO: 15) Thus, among the provided anti-MMP9 antibodies are antibodies having a heavy chain CDRl region with an amino acid ce as set forth in SEQ ID NO: 13, dies having a heavy chain CDR2 region with an amino acid sequence set forth in SEQ ID NO: 14, and antibodies having a heavy chain CDR3 region with an amino acid sequence as set forth in SEQ ID NO: 15, and antibodies that compete for binding with or bind to the same epitope on MMP9 as such dies. In some cases, the antibodies contain VH CDRs having the sequences set forth in SEQ ID NO: l3, l4, and 15.

In some embodiments, the CDRs of the light chain of exemplary anti-MMP9 antibodies as sed herein have the following amino acid ces: CDRl: MSQDVRNTVA (SEQ ID NO: 16) CDR2: T (SEQ ID NO:17) CDR3: QQHYITPYT (SEQ ID NO:18) Thus, among the provided anti-MMP9 antibodies are antibodies having a light chain CDRl region with an amino acid sequence as set forth in SEQ ID NO: 16, antibodies having a light chain CDR2 region with an amino acid sequence set forth in SEQ ID NO: 17, and antibodies having a light chain CDR3 region with an amino acid sequence as set forth in SEQ ID NO: 18, and antibodies that compete for binding with or bind to the same epitope on MMP9 as such antibodies. In some cases, the dies contain VL CDRs having the sequences set forth in SEQ ID NO: l6, l7, and 18.

WO 30078 Nucleic acids encoding anti-MMP9 antibodies The present disclosure provides nucleic acids encoding anti-MMP9 antibodies and functional fragments thereof. Accordingly, the present disclosure provides an isolated polynucleotide (nucleic acid) encoding an antibody or antigen-binding fragment as described herein, vectors containing such polynucleotides, and host cells and expression systems for ribing and ating such polynucleotides into polypeptides.

The present disclosure also contemplates constructs in the form of plasmids, vectors, transcription or expression cassettes which comprise at least one polynucleotide as above.

The t disclosure also provides a recombinant host cell which comprises one or more constructs as above, as well as methods of production of the antibody or antigen-binding nts thereof described herein which method comprises expression of nucleic acid encoding a heavy chain polypeptide and a light chain polypeptide (in the same or different host cells, and from the same or different constructs) in a recombination host cell. Expression can be achieved by culturing under appropriate conditions recombinant host cells containing the nucleic acid.

Following production by sion, an antibody or antigen-binding fragment can be isolated and/or purified using any suitable que, then used as appropriate.

Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, mammalian cells, yeast and baculovirus s. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, NSO mouse melanoma cells and many others. A common bacterial host is E. coli.

Suitable vectors can be chosen or constructed, containing appropriate regulatory ces, including operably linked promoter sequences, ator sequences, polyadenylation sequences, enhancer sequences, marker genes and/or other ces as appropriate. Vectors can be plasmids, viral e. g. ‘phage, or phagemid, as appropriate. For r details see, for e, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, nesis, sequencing, introduction of DNA into cells and gene expression, and is of proteins, are described in detail in Short Protocols in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992. The disclosures of Sambrook et al. and Ausubel et al. are orated herein by reference in their entirety.

The nucleic acid ng a polypeptide of interest is integrated into the genome of the host cell or can be maintained as a stable or transient episomal element.

Any of a wide variety of expression control sequences — sequences that control the expression of a DNA ce operatively linked to it — can be used in these vectors to express the DNA sequences. For example, a c acid encoding a polypeptide of interest can be operably linked to a er, and provided in an expression construct for use in methods of production of recombinant MMP9 proteins or portions thereof.

Those of skill in the art are aware that nucleic acids encoding the antibody chains disclosed herein can be synthesized using standard knowledge and procedures in molecular biology.

Examples of nucleotide sequences encoding the heavy and light chain amino acid sequences disclosed herein, are as follows: VI“; CAGC TGCAGGAATC CGGCCCTGGC CTGGTCAAGC CCTCCGAGAC ACTGTCCCTG ACCTGCACCG TGTCCGGCTT CTCCCTGCTG TCCTACGGCG TGCACTGGGT CCGACAGCCT CCAGGGAAGG GCCTGGAATG GCTGGGCGTG ATCTGGACCG GCGGCACCAC CAACTACAAC TCCGCCCTGA TGTCCCGGCT GACCATCTCC AAGGACGACT CCAAGTCCAC CCTG AAGATGAACT CCCTGAAAAC CGAGGACACC GCCATCTACT ACTGCGCCCG GTACTACTAC GGCATGGACT ACTGGGGCCA GGGCACCTCC GTGACCGTGT CCTCA (SEQ ID N0219) ‘HIE CAGC TGCAGGAATC CGGCCCTGGC CTGGTCAAGC CCTCCGAGAC ACTGTCCCTG ACCTGCACCG TGTCCGGCTT CTCCCTGCTG TCCTACGGCG TGCACTGGGT CCGACAGCCT CCAGGCAAAG GCCTGGAATG GCTGGGCGTG ATCTGGACCG CCAC CAACTACAAC CTGA TGTCCCGGCT GACCATCTCC AAGGACGACT CCAAGAACAC CGTGTACCTG AAGATGAACT CCCTGAAAAC CGAGGACACC GCCATCTACT CCCG GTACTACTAC GGCATGGACT ACTGGGGCCA GGGCACCCTG GTCACCGTGT CCTCA (SEQ ID NO:20) \qfi CAGGTGCAGC TGCAGGAATC CGGCCCTGGC CTGGTCAAGC CCTCCGAGAC ACTGTCCCTG ACCTGCACCG TGTCCGGCTT CTCCCTGCTG TCCTACGGCG TGCACTGGGT CCGACAGCCT CCAGGCAAAG AATG GCTGGGCGTG ATCTGGACCG GCGGCACCAC CAACTACAAC TCCGCCCTGA GGTT CACCATCTCC GACT CCAAGAACAC CCTG AACT CCCTGAAAAC CGAGGACACC GCCATCTACT ACTGCGCCCG GTACTACTAC GGCATGGACT ACTGGGGCCA GGGCACCCTG GTCACCGTGT CCTCA (SEQ ID NO:21) VV()2013/130078 2012/027160 VH4: CAGGTGCAGC TGCAGGAATC CGGCCCTGGC CTGGTCAAGC CCTCCGAGAC ACTGTCCCTG ACCTGCACCG TGTCCGGCTT CTCCCTGCTG TCCTACGGCG TGCACTGGGT CCGACAGCCT CCAGGCAAAG GCCTGGAATG GCTGGGCGTG ATCTGGACCG GCGGCACCAC CAACTACAAC CTGA GGTT CACCATCTCC AAGGACGACT CCAAGAACAC CCTGTACCTG AAGATGAACT CCCTGAAAAC CGAGGACACC GCCATCTACT ACTGCGCCCG CTAC GGCATGGACT ACTGGGGCCA CCTG GTCACCGTGT CCTCA (SEQ ID N022) Vkl: GACATCGTGA TGACCCAGTC CCCCAGCTTC CTGTCCGCCT CCGTGGGCGA CAGAGTGACC ATCACATGCA AGGCCTCTCA GGACGTGCGG AACACCGTGG CCTGGTATCA GCAGAAAACC GGCAAGGCCC CCAAGCTGCT GATCTACTCC TCCTCCTACC GGAACACCGG CGTGCCCGAC CGGTTTACCG GCTCTGGCTC CGGCACCGAC TTTACCCTGA CCATCAGCTC CCTGCAGGCC GAGGACGTGG CCGTGTACTT CTGCCAGCAG CACTACATCA CCCCCTACAC CTTCGGCGGA GGCACCAAGG TGGAAATAAA A (SEQ ID N023) Vk2: GACATCGTGA TGACCCAGTC CCCCTCCAGC CTGTCCGCCT GCGA CAGAGTGACC ATCACATGCA AGGCCTCTCA GGACGTGCGG AACACCGTGG CCTGGTATCA GCAGAAGCCC GGCAAGGCCC CCAAGCTGCT GATCTACTCC TCCTCCTACC GGAACACCGG CGTGCCCGAC CGGTTTACCG GCTCTGGCTC CGGCACCGAC TTTACCCTGA CCATCAGCTC CCTGCAGGCC GAGGACGTGG CCGTGTACTT CTGCCAGCAG CACTACATCA CCCCCTACAC CTTCGGCGGA GGCACCAAGG TGGAAATAAA A (SEQ ID N024) Vk3: GACATCCAGA TGACCCAGTC CAGC CTGTCCGCCT CTGTGGGCGA CAGAGTGACC ATCACATGCA CCCA GCGG GTGG CCTGGTATCA GCAGAAGCCC GGCAAGGCCC CCAAGCTGCT GATCTACTCC TCCTCCTACC GGAACACCGG CGTGCCCGAC CGGTTCTCTG GCTCTGGAAG CGGCACCGAC TTTACCCTGA CCATCAGCTC CCTGCAGGCC GAGGACGTGG CCGTGTACTT CTGCCAGCAG CACTACATCA CCCCCTACAC CGGA AAGG TGGAAATAAA A (SEQ ID N025) Vk4: GACATCCAGA TGACCCAGTC CCCCTCCAGC CTGTCCGCCT CTGTGGGCGA CAGAGTGACC ATCACATGCA AGGCCTCTCA GGACGTGCGG AACACCGTGG CCTGGTATCA GCCC GGCAAGGCCC CCAAGCTGCT GATCTACTCC TCCTCCTACC GGAACACCGG CGTGCCCGAC CGGTTCTCTG GCTCTGGAAG CGGCACCGAC TTTACCCTGA CCATCAGCTC CCTGCAGGCC GAGGACGTGG CCGTGTACTA CTGCCAGCAG CACTACATCA CCCCCTACAC CTTCGGCGGA AAGG TGGAAATAAA A(SEQ ID No:26) Because the structure of antibodies, including the juxtaposition of CDRs and framework regions in the le region, the structure of framework regions and the structure of heavy- and light-chain constant regions, is well-known in the art; it is well within the skill of the art to obtain related nucleic acids that encode MP-9 antibodies. Accordingly, polynucleotides comprising nucleic acid sequences having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% and at least 99% homology to any of the nucleotide ces disclosed herein are also provided. Accordingly, polynucleotides comprising nucleic acid sequences having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% and at least 99% identity to any of the nucleotide sequences disclosed herein are also provided. In one example, the polynucleotide contains at least at or about 75 %, 80 %, 85 %, 90 %, 9l %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity with SEQ ID NO: 21 or includes or is SEQ ID NO: 21 and/or contains at least at or about 75 %, 80 %, 85 %, 90 %, 9l %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity with SEQ ID NO: 26 or es or is SEQ ID NO: 26.

Pharmaceutical Compositions MMP9 binding proteins, as well as nucleic acid (e.g., DNA or RNA) encoding MMP9 binding proteins, can be provided as a pharmaceutical composition, e.g., combined with a pharmaceutically acceptable carrier or excipient. Such ceutical compositions are useful for, for example, administration to a subject in vivo or ex vivo, and for diagnosing and/or treating a subject with the MMP9 binding proteins, such as in any of the therapeutic or diagnostic methods provided herein.

Pharmaceutically able rs are physiologically acceptable to the stered patient and retain the therapeutic properties of the dies or es with which it is administered. Pharmaceutically-acceptable carriers and their formulations are and generally bed in, for example, Remington’ ceutical Sciences (18th Edition, ed. A.

Gennaro, Mack Publishing Co., Easton, PA 1990). One exemplary pharmaceutical carrier is physiological saline. Each carrier is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of the formulation and not substantially injurious to the patient.

Pharmaceutical compositions can be formulated to be compatible with a particular route of administration, systemic or local. Thus, pharmaceutical compositions include carriers, diluents, or excipients suitable for administration by s routes.

Pharmaceutical compositions can include pharmaceutically acceptable additives.

Examples of additives include, but are not limited to, a sugar such as mannitol, sorbitol, glucose, xylitol, trehalose, sorbose, sucrose, galactose, dextran, se, fructose, lactose and mixtures f. ceutically able ves can be combined with ceutically acceptable carriers and/or excipients such as dextrose. Additives also include surfactants such as polysorbate 20 or rbate 80.

The formulation and delivery methods will generally be adapted ing to the site and the disease to be treated. Exemplary formulations include, but are not limited to, those suitable for parenteral administration, e. g., intravenous, intra-arterial, intramuscular, or subcutaneous administration, or oral administration.

Pharmaceutical compositions for parenteral delivery include, for example, water, saline, phosphate buffered saline, Hank’s on, Ringer’s solution, dextrose/saline, and glucose solutions. The formulations can n auxiliary substances to approximate physiological conditions, such as buffering agents, ty adjusting agents, wetting agents, detergents and the like. Additives can also include additional active ingredients such as bactericidal agents, or stabilizers. For example, the solution can contain sodium acetate, sodium lactate, sodium chloride, ium chloride, calcium chloride, sorbitan monolaurate or triethanolamine oleate. Additional parenteral formulations and methods are described in Bai (1997) J. Neuroimmunol. 80:65 75; Warren (1997) J. Neurol. Sci. 152:31 38; and Tonegawa (1997) J. Exp. Med. 186507 515. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions for intradermal or subcutaneous administration can include a e diluent, such as water, saline solution, fixed oils, polyethylene glycols, ine, propylene glycol or other synthetic solvents; cterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid, glutathione or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.

Pharmaceutical compositions for injection include s solutions (Where water soluble) or dispersions and e powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable rs e physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ.) or phosphate buffered saline (PB S). The carrier can be a solvent or dispersion medium containing, 2012/027160 for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. Fluidity can be maintained, for example, by the use of a g such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Antibacterial and antifungal agents include, for example, ns, chlorobutanol, , ascorbic acid and thimerosal. Isotonic agents, for example, sugars, polyalcohols such as l, sorbitol, and sodium chloride may be hmwwmmmmmmmnTmeMgmMmeMwmwgwbwmfimmr lyophilized; the lyophilized preparation can later be combined with a sterile solution prior to administration.

Pharmaceutically acceptable carriers can contain a compound that stabilizes, increases, or delays absorption or clearance. Such compounds include, for example, carbohydrates, such as glucose, sucrose, or dextrans; low molecular weight proteins; compositions that reduce the clearance or hydrolysis of es; or excipients or other stabilizers and/or s. Agents that delay absorption include, for e, aluminum ImWMwmmwdgmm.mmgmmwnwmmmmdwmwmmoHMmmfimn®awmme absorption of the pharmaceutical composition, including liposomal carriers. To protect from digestion the nd can be complexed with a composition to render it resistant to acidic and enzymatic hydrolysis, or the compound can be xed in an appropriately resistant carrier such as a liposome. Means of protecting compounds from digestion are known in the art (see, egfllhx(l996)Phananes 1&17601764;Sanwnen(l996)J.Phann.Phannaafl 48 119135; and US. Pat. No. 5,391,377, describing lipid itions for oral delivery of eutic agents) Compositions of the present invention can be combined with other therapeutic moieties or imaging/diagnostic moieties as provided herein. Therapeutic moieties and/or im®gmdfiawflwmwmwfiammmmwmmmmmm%awmgmfimmefimt on an MMP9 binding protein.

Formulations for in vivo administration are generally sterile. In one embodiment, the pharmaceutical compositions are formulated to be free of pyrogens such that they are acceptable for stration to human patients.

Various other pharmaceutical compositions and techniques for their preparation and use will be known to those of skill in the art in light of the present disclosure. For a detailed listing of suitable pharmacological compositions and associated administrative techniques one can refer to the detailed teachings , which can be further supplemented by texts such as Remington: The Science and Practice of Pharmacy 20th Ed. (Lippincott, ms & Wilkins 2003).

WO 30078 Pharmaceutical compositions can be ated based on the physical characteristics of the patient/subject needing treatment, the route of administration, and the like. Such can be packaged in a suitable pharmaceutical package with appropriate labels for the distribution to hospitals and clinics wherein the label is for the indication of treating a er as described herein in a subject. Medicaments can be packaged as a single or multiple units. Instructions for the dosage and administration of the pharmaceutical compositions of the present invention can be included with the pharmaceutical packages and kits described below.

Methods ofUse The MMP9 binding proteins, ing anti-MMP9 dies and fragments f, of the present disclosure can be used, for example, in therapeutic and diagnostic methods, such as methods of detection of MMP9 in a sample, methods of treatment (e.g., as in methods of inhibition of angiogenesis), and methods of diagnosis and prognosis. Thus, provided are diagnostic and therapeutic methods and uses of the anti-MMP9 antibodies. Examples of methods of use are described below.

Methods of Treatment Provided herein are methods of ent, including methods of treating diseases and disorders associated with MMP9 expression and/or activity, as well as uses of the provided antibodies and compositions in such methods. The diseases and disorders include, but are not limited to cancer, e. g., tumors (e. g., primary or metastatic ), such as those that express or are disposed in a tissue which expresses MMP9, and inflammatory diseases, such as inflammatory bowel diseases, rheumatoid arthritis and inflammatory myopathies.

As used herein, “treat” or “treatment” means stasis or a postponement of development of one or more symptoms associated with a disease or disorder bed herein, or ameliorating existing uncontrolled or unwanted ms, preventing additional symptoms, or ameliorating or ting the ying metabolic causes of symptoms. Thus, the terms denote that a beneficial result has been red on a mammalian subject with a disease or symptom, or with the potential to develop such disease or symptom. A response is achieved when the patient experiences partial or total alleviation, or reduction of signs or symptoms of illness, and can include, without limitation, prolongation of survival. The expected progression- free al times can be measured in months to years, depending on prognostic factors ing the number of relapses, stage of disease, and other factors. 2012/027160 Also provided are pharmaceutical compositions for use in connection with such methods, such as those containing any of the antibodies or nts thereof described .

Compositions can be suitable for administration locally or systemically by any le route.

In general, MMP9 binding proteins are administered in a therapeutically effective amount, e. g., in an amount to effect inhibition of tumor growth in a subject, to inhibit metastasis, to inhibit inflammation, to inhibit tissue destruction, to inhibit MMP9 activity, or to treat the particular disease or condition associated with MMP9.

As used herein, unless ise specified, the term “therapeutically effective amount” or “effective amount” refers to an amount of an agent or compound or composition that when stered (either alone or in combination with r therapeutic agent, as may be specified) to a subject is effective to prevent or ameliorate the disease condition or the progression of the disease, or result in amelioration of symptoms, e. g., treatment, healing, tion or amelioration of the relevant medical condition, or an se in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient administered alone, a therapeutically effective dose refers to that ingredient alone.

When applied to a ation, a therapeutically ive dose refers to ed amounts of the active ients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. In one example, when in vivo administration of an anti-MMP9 antibody is employed, normal dosage amounts can vary from about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day, preferably about 1 day to 50 mg/kg/day, optionally about 100 ug/kg/day to 20 mg/kg/day, 500 ug/kg/day to 10 mg/kg/day, or 1 mg/kg/day to 10 day, depending upon the route of administration. In one embodiment, intravenous dosage range from about 1 mg/kg to about 30 mg/kg. In some embodiments, intravenous dosages range from at or about 1 mg/kg to at or about 14 mg/kg, such as from at or about 2 mg/kg to at or about 14 mg/kg, ql4d, once every 14 days. In other embodiments, subcutaneous dosages range from at or about 1 mg/kg to at or about 28 mg/kg, such as from at or about 2 mg/kg to at or about 28 mg/kg, ql4d, once every 14 days. In some embodiments, the effective amount of dosage is administered once every 7 to 28 days. In one embodiment, the effective amount of dosage is administered once every 7 days. In another embodiment, the effective amount of dosage is administered once every 28 days.

The selected dosage regimen will depend upon a variety of factors including the activity of the MMP9 binding protein, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular composition employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like s well known in the medical arts.

A clinician having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian can start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

In some cases, the methods of treatment e parenteral administration, e. g., intravenous, intra-arterial, intramuscular, or subcutaneous administration, or oral administration of the agent, e.g., anti-MMP9 antibody or composition containing the same.

As used herein, the term "subject" means a mammalian subject. Exemplary subjects include, but are not limited to humans, s, dogs, cats, mice, rats, cows, horses, goats and sheep. In some ments, the subject has cancer, an inflammatory disease or condition, or an autoimmune disease or condition, and can be treated with the agent of the present invention as described below.

If needed, for ents, methods can further include additional therapies, such as in the case of cancer, surgical removal of the cancer and/or stration of an ancer agent or ent in addition to an MMP9 binding protein. Administration of such an anti-cancer agent or treatment can be concurrent with administration of the compositions disclosed herein.

Methods of Detection of MMP9 The present disclosure also contemplates methods of detecting MMP9 in a subject, e. g., to detect tumor or tumor-associated tissue expressing MMP9, or tissue or fluid or other biological sample ated with a disease as described , such as autoimmune or inflammatory e. Thus, methods of sing, monitoring, staging or detecting a tumor having MMP9 activity are provided.

Samples (e.g., test biological samples) from a subject (e. g., an individual suspected of having or known to have a tumor associated with MMP9 expression, or suspected of having or known to have r disease or condition), can be analyzed for MMP9 presence, e, expression, and/or levels. For example, such samples can be collected and analyzed by detecting the presence or absence of binding of an MMP9 binding protein, such as an antibody or fragment as described herein, to substance (e. g., protein) in the sample. In some examples, the methods further include ing the amount of binding detected to an amount of binding to a control sample, or comparing the detected level of MMP9 to a control level of MMP9. In some cases, the methods indicate the ce, absence, or severity of an MMP9-associated disease or condition, such as one described herein.

This analysis can be performed prior to the initiation of treatment using an MMP9 binding protein as described herein, or can be done as part of monitoring of progress of cancer treatment. In some embodiments, provided are methods of treatment, carried out by ming the detection assays and initiating, altering, or discontinuing treatment of the t, for e, based on the results of the diagnostic assay. Such diagnostic analysis can be performed using any , including but not limited to tissue, cells isolated from such tissues, and the like. In some cases, the methods are performed on liquid samples, such as blood, plasma, serum, whole blood, saliva, urine, or semen. Tissue samples include, for e, formalin-fixed or frozen tissue sections.

Any suitable method for detection and analysis of MMP9 can be employed. Various diagnostic assay techniques known in the art can be adapted for such purpose, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or neous phases.

MMP9 binding proteins for use in detection methods can be d with a detectable moiety. The detectable moiety directly or indirectly produces a detectable signal. For example, the detectable moiety can be any of those described herein such as, for e, a radioisotope, such as 3H, 14C, 32F, 358, or 1251, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate (PTTC), Texas red, cyanin, photocyan, rhodamine, or luciferin, or an enzyme, such as ne phosphatase, B-galactosidase or horseradish peroxidase.

Detection can be accomplished by contacting a sample under conditions suitable for MMP9 binding protein binding to MMP9, and assessing the presence (e.g., level) or e of MMP9 binding protein-MMP9 complexes. A level of MMP9 in the sample in comparison with a level of a nce sample can indicate the presence of a tumor or tumor-associated tissues having MMP9 activity. The reference sample can be a sample taken from the subject at an earlier time point or a sample from r individual.

Various aspects of the invention are further described and illustrated by way of the l examples which , none of which are intended to limit the scope of the invention.

EXAMPLES Example 1A: Preparation of antibodies to human MMP-9.

The full-length human MMP9 protein without a signal peptide (SEQ ID NO. 28) was used to immunize mice. Spleen cells from immunized mice were fused with myeloma cells to te a hybridoma library. Monoclonal cultures were ed and screened to identify cultures expressing an anti-MMP9 monoclonal antibody.

An dy (AB0041) was purified from one of the cultures and characterized. This antibody contained an IgG2b heavy chain and a kappa light chain. Characterization included testing for the g of AB0041 to other human MMPs and to MMP9 proteins from other species, including cynomolgus monkey, rat and mouse. As shown in Table 2, the AB0041 antibody had greater ty to human and cynomolgus MMP9, that it had lower affinity to rat MMP9. In addition, the AB0041 antibody did not bind to murine MMP9 or to many human non-MMP matrix metalloproteinases.

Table 2: Cross reactivity of AB0041 and AB0045 MMP Tested Dissociation constant (Kd) AB0045 AB0041 Human MMPl Human MMP2 Mouse MMP2 Human MMP3 Human MMP7 Human MMP8 >100 nM >100 nM Human MMP9 0.168 i 0.117 nM 0.133 i 0.030 nM Cynomolgus monkey 0.082 i 0.022 nM 0.145 i 0.16 nM MMP9 Mouse MMP9 Rat MMP9 0.311 i 0.017 nM 0.332 i 0.022 nM Human MMP10 >100 nM >100 nM Human MMP12 >100 nM >100 nM Human MMP13 >100 nM >100 nM Additional characterization included assaying the binding of AB0041 to mutant mouse and human MMP9 proteins. Non-identical residues in the catalytic domain of mouse and human MMP9 proteins were identified, and forty-six non-identical amino acid residues were selected for mutagenesis. Most mutations were generated in mouse MMP9: the mouse amino acid residues were mutated to match those of human MMP9. Other mutations were generated in human MMP9: the human amino acid residues were mutated to match those of mouse MMP9.

The mutated mouse or human MMP9 proteins were used in an ELISA assay.

In the ELISA assay, the AB0041 antibody was used as the primary antibody and a goat anti-mouse IgG dy conjugated to horseradish peroxidase was used to detect the g. The wild-type human MMP9 was used a positive control and the ype mouse MMP9 was used as a negative control. The results of the ELISA assay showed an arginine residue at position 162 of the MMP9 amino acid sequence (R162) as important for the MMP9 binding of the AB0041 antibody. The results also showed the amino acid residues E111, D113, and 1198 were important for the MMP9 binding of the AB0041 antibody. Based on the crystal structure of MMP9, E111, D113, R162, and 1198 are grouped near each other around a Ca2+ ion g pocket of MMP9. In this study, the AB0041 antibody was shown to specifically bind to an epitope containing amino acid es within regions of MMP9 containing amino acid residues 104-119, 159-166, and 191-202.

In an enzymatic assay for MMP9, the AB0041 antibody was found to act as a non- competitive inhibitor of MMP9.

Example 1B: Preparation of additional antibodies to human MMP-9. onal hybridomas were ted, which produced antibodies having variable s that shared identity with AB0041. One such hybridoma, designated M4, expressed an antibody containing the heavy chain (IgG2b) sequence: MAVLVLFLCLVAFPSCVLSQVQLKESGPGLVAPSQSLSITCTVSGFSLLSYGV HWVRQPPGKGLEWLGVIWTGGSTNYNSALMSRLSISKDDSKSQVFLKMNSLQTDDTA MYYCARYYYAMDYWGQGTSVTVSSAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPE SVTVTWNSGSLSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDKKLEPS GPISTINPCPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVRI SWFVNNVEVHTAQTQTHREDYNSTIRVVSALPIQHQDWMSGKEFKCKVNNKDLPSPIERTISK APQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKDTAPVLDSD GSYFIYSKLDIKTSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPGK (SEQ ID NO:30) (signal e set forth in underlined text, variable region set forth in plain text, and constant region set forth in s), and the light chain (kappa) sequence: MESS 21g QVFVFVFLWLSGVDGDIVMTQSHKFMFTSVGDRVSITCIQASQDVRNT VAWYQQKTGQSPKLLIYSASYRNTGVPDRFTGSISGTDFTFTISSVQAEDLALYYCQQH YSTPYTFGGGTKLEVKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSE RQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (signal peptide set forth in underlined text, variable region set forth in plain text, and constant region set forth in italics) (SEQ ID NO: 31).

The M4 antibody had a variable heavy chain with an amino acid sequence: QVQLKESGPGLVAPSQSLSITCTVSGFSLLSYGVHWVRQPPGKGLEWLGM TGGSTNYNSALMSRLSISKDDSKSQVFLKMNSLQTDDTAMYYCARYYYAMDYWGQG TSVTVSS (CDRs 1, 2, and 3 (SEQ ID NOs: 34, 35, and 36, respectively) underlined) (SEQ ID NO: 32) and a variable light chain with the amino acid sequence SHKFMFTSVGDRVSITCKASSzDVRNTVAWYQQKTGQSPKLLIYw YRNTGVPDRFTGSISGTDFTFTISSVQAEDLALYYCS 2g QHYSTPYTFGGGTKLEVK (CDRs l, 2, and 3 (SEQ ID NOS: 37, 38, and 39, respectively) underlined) (SEQ ID NO: 33).

Another such hybridoma, designated Ml2, expressed only a kappa chain, having the sequence: MLLWLSGVDGDIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVA GQSPMLIYSASYRFSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNS YPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQ NGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (signal peptide set forth in underlined text, variable region set forth in plain text, and constant region set forth in italics) (SEQ ID NO: 40).

The Ml2 antibody had a variable light chain with the amino acid sequence DIVMTQSQKFMSTSVGDRVSVTCKASgzNVGTNVAWYQQKPGQSPKALIYfi SYRFSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCS 2g QYNSYPYTFGGGTKLEIK (CDRs l, 2, and 3 (SEQ ID NOs: 42, 43, and 44, respectively) underlined) (SEQ ID NO: 41).

A sequence ison, showing differences between the M4 and M12 heavy and light chains as compared with AB004l antibody is shown in Figure 4.

An enzymatic assay was carried out. The results trated that the antibodies produced by the M4 and M12 hybridomas acted as non-competitive inhibitors of MMP9 (data not shown).

Example 1C: Preparation of antibodies to mouse MMP-9.

Another mouse antibody, AB0046, was generated. Using a process similar to that described in Example 1A, the MMP9-knockout mice n B6.FVB (Cg)- MmeWITW/J) was immunized using targeted domains of the pro/catalytic domain fragment of murine MMP9. The AB0046 antibody had a kappa light chain with an amino acid sequence MSSAS LLCFQ QGTRCDIQMTQTTSSLSASLGDRVTISCSASQGISNYLNWYQQKPD GTFKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYGWLPRTFGGGT KLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTD QDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 45) (signal peptide set forth in underlined text, variable region set forth in plain text, and nt region set forth in italics) and an IgGl heavy chain with an amino acid sequence MGWSSIILFLVATATGVHSQVQLQQPGSVLVRPGASVKLSCTASGYTFTSYWMNWVK QRPGQGLEWIGEIYPISGRTNYNEKFKVILATLTVDTSSSTAYMDLNSLTSEDSAVYYCA RSRANWDDYWGQGTTLTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVT WNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGC KPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQP REEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPP KEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKS NWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK (SEQ ID NO: 46) (signal peptide set forth in underlined text, variable region set forth in plain text, and nt region set forth in italics).

The following amino acid sequence comprises the framework regions and complementarity-determining regions (CDRs) of the variable region of the IgGl heavy chain of AB0046 (with CDRs underlined): QVQLQQPGSVLVRPGASVKLSCTASGYTPTSYWMNWVKQRPGQGLEWIGE YPISGRTNYNEKFKVIQATLTVDTSSSTAYMDLNSLTSEDSAVYYCARSRANWDDYWG QGTTLTVSS (SEQ ID No: 47).

The ing amino acid sequence comprises the framework s and complementarity-determining regions (CDRs) of the variable region of the kappa light chain of AB0046 (with CDRs underlined): DIQMTQTTSSLSASLGDRVTISCSASQQGISNYLNWYQQKPDGTFKLLIYYTSIL H_SGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCS 2g RTFGGGTKLEIK (SEQ ID No: 48) Additional characterizations showed that the AB0046 antibody bound to mouse MMP9 non-competitively or its binding was not dependant on the concentration of mouse MMP9. The AB0046 antibody did not bind to human MMP9 or MMP2, mouse MMP2, 3, 7, 8, or 12. Using e analysis as described in Example 1A, it was shown that the proline residue at position 162 of the mouse MMP9 amino acid sequence (P162) (corresponding to R162 of human MMP9) was important for the MMP9 binding of the AB0046 antibody. The s suggested that the AB0046 antibody specifically bound to an epitope containing a residue within a n of mouse MMP9 corresponding to the portion containing amino acids 159-166 of human MMP9. Thus, the AB0046 antibody was an inhibitory antibody specific to mouse MMP9 and had similar kinetics of binding and inhibition as those of AB0041. Because AB0046 is specific to mouse MMP9 and binds to an e as AB0041/AB0045, AB0046 is suitable for assays which uses either AB0041 or AB0045.

Further terization showed that the AB0046 antibody was a murine IgGl e, having a limited effector function in mouse.

Three other mouse anti-MMP9 antibodies were generated using similar methods, which were non-inhibitory and for which P162 was important for binding. 2012/027160 Example 2: Humanization of antibodies to human MMP9 The amino acid sequences of the heavy chain and light chain of the mouse AB0041 antibody were altered at certain locations in the framework (i.e., non-CDR) portion of their le regions to generate proteins that are less immunogenic in humans. These amino acid sequence s were shown in Figures 1 and 2. The cross-reactivity of one humanized antibody, referred to as AB0045, is shown in Table 2A above.

The humanized variant anti-MMP9 antibody, AB0045 (humanized, modified IgG4 (S241P); see Example 2, above) contained the humanized AB0041 heavy chain t VH3 (having the sequence set forth in SEQ ID NO: 7 (QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVI WTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQ GTLVTVSS) and the humanized AB0041 light chain variant VH4 (having the light chain sequence set forth in Vk4 (having the sequence set forth in SEQ ID NO: 12 (DIQMTQSPSSLSASVGDRVTITCIQASQDVRNTVAWYQQKPGILAPKLLIYSSS YRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK)).

The heavy chain of the AB0045 antibody has the sequence set forth in SEQ ID NO: ILLFLVAVATRVHSQVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQ PPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCAR YWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLP PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKS RWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (signal sequence underlined; sequence of the constant region presented italics)); the light chain of the AB0045 antibody has the sequence set forth in SEQ ID NO: 50 (MRVPAS QLLGLLLLWLPGARCDIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQ QKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYT FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC l sequence underlined; sequence of the constant region presented italics)). The antibody contains 1312 amino acids in length, is composed of two heavy chains and two light chains, and has a theoretical pI of about 7.90, extinction coefficient of about 1.50 AU/cm at 280 nm for 1 g/L, a molecular weight of about 144 kDa, and density of about 1 g/mL in formulation buffer (50-100 mg/mL product concentration).

Further characterization of this antibody is described in Example 3, below.

Example 3: Characterization of variant MMP9 antibody AB0045 and comparison to AB0041 and AB0046 As described above, AB0045 and AB0041 antibodies are mpetitive inhibitors of MMP9. Thus, both antibodies inhibit MMP9 tic activity ndently of substrate concentration. The AB0045 antibody binds to the same MMP9 epitope as the AB0041 antibody with an affinity in the 1 x 10-12 molar range, as shown by direct binding and surface plasmon resonance (SPR) assays. Both antibodies are specific for MMP9, with no significant non- specific binding observed against other purified protein targets including purified domains and full length forms of MMP enzymes. Both AB0045 and AB0041 antibodies are cross-reactive with native and recombinant human and recombinant rat and cynomolgus monkey MMP9.

The in vitro binding affinity, inhibition characteristics, and the specificity of the antibodies of AB0045, AB0041 and AB0046 for MMP9 of human and non-human origin were determined using Enzyme-Linked Immunosorbent Assay (ELISA) and an MMP9 enzymatic assay. SPR analysis was also used to generate dissociation constants (Kd) of AB0045 and AB0041.

In the ELISA assay, the Kd value of AB0045 and AB0041 antibodies for human, cynomolgus , and rat MMP9 derived from ELISA were all found to be <400 pM. The ELISA data illustrated that both AB0045 and AB0041 antibodies react with MMP9 from all the relevant logy species . The AB0046 antibody was shown to be specific to mouse MMP9 and therefore could be used as a surrogate antibody in mouse efficacy models.

The s showed that the Kd value of the AB0045 antibodies for human MMP9 was 0.168 i 0.117 nM and the and Kd value of the AB0041 dy was 0.133 i 0.030 nM. The results on the AB0046 antibodies showed it bound to mouse MMP9 with the Kd value of 0.218 i 0.097 nM. In the SPR analysis, the results showed that the Kd values of AB0045 and AB0041 antibodies for human MMP9 were 8.8 pM and 0.4 pM, respectively.

The enzymatic inhibitory ties of AB0045, AB0041, and AB0046 antibodies were evaluated in an assay assessing MMP9-mediated cleavage of a fluorogenic e substrate Mca-PLGL-Dpa-AR-NHZ. All three antibodies inhibited MMP9 enzyme ty. The IC50 values of AB0045 (0.691 i 0.097 nM) and AB0041 (0.569 i 0.185 nM) for human MMP9 were not statistically different. The IC50 value for the AB0046 inhibition of mouse MMP9 was 0.352 i 0.03 nM. The value was not adjusted for the concentration of active enzyme that was generated during the preparation. Additional MMP9 tic assay under steady-state conditions was used to determine IC50 and mode of inhibition. In this assay, the IC50 values of AB0045 ranged from 0.148 nM to 0.161 nM in a d range of substrate concentration, and in one e is 0.158 anhe results showed that the MMP9 inhibitory activity of AB0045 was mpetitive.

Table 2B: Binding and Inhibitory Properties of AB0045, AB0041, and surrogate mouse antibody AB0046 AB0045 AB0041 AB0046 ELISA Human MMP9 0.168 i 0.117 nM 0.133 i 0.030 nM >100 nM Dissociation constant Cynomolgus monkey 0.082 i 0.022 nM 0.145 i 0.16 nM >100 nM MMP9 Dissociation constant Mouse MMP9 >100 nM >100 nM 021810.097 nM Dissociation constant Rat MMP9 0.311 i 0.017 nM 0.332 i 0.022 nM >100 nM Dissociation constant Human MMP9 8.8pM 0.4pM ND Dissociation constant Activit Assa Human MMP9 IC50 0.691 i 0.097 nM 0.569 1 0.185 nM Cynomolgus monkey 0.194 i 0.048 nM* 0.189 i 0.019 nM* MMP9 IC50 Rat MMP9 ICso 8.23 i 1.24 nM* 2.78 i 1.17 nM * Mouse MMP9 ICso 0.352i0.03 nM* The results confirmed that AB0045 and AB0041 have lent binding and inhibitory properties and that AB0046 can serve as a relevant mouse surrogate antibody, for example, in mouse models of human disease.

Claims (10)

1. A method of detecting human MMPQ in a sample, comprising: a) contacting the sample with an antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region and a light chain le (VL), wherein the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 34, a CDR2 sing the amino acid sequence set forth in SEQ ID NO: 35, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 36; wherein the light chain variable domain (VL) comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39; and b) detecting binding of the antibody or antigen—binding fragment thereof to human MMP9 in the sample, thereby detecting the presence or absence of the human MMPQ.

2. The method of claim 1 further comprising the step of ing the amount of binding detected in the sample to an amount of binding to a control sample.

3. The method of claim 1 or 2, wherein the sample is a tissue or fluid sample from a subject.

4. The method of claim 3, wherein the fluid sample is a blood, plasma, serum, whole blood, saliva, urine, or semen sample.

5. The method of claim 3, wherein the tissue sample is a formalin—fixed sample or a frozen sample.

6. The method of any one of claims 1 to 5, wherein the antibody or antigen-binding nt thereof is labeled with a able moiety.

7. The method of claim 6, wherein the label moiety is radioisotope, a fluorescent or chemiIuminescent compound, or an enzyme. 1001622999

8. The method of any of claims 1 to 7, wherein the heavy chain variable (VH) region comprises the amino acid sequence set forth in SEQ ID NO: 32.

9. The method of any one of claims 1 to 8, wherein the light chain variable (VL) region comprises the amino acid sequence set forth in SEQ ID NO: 33.

10. The method of detecting human MMP9 in a sample according to claim 1 ntially as hereinbefore described.